Nutra Pharma, a biotech company developing treatments for neurological disorders, cancer, autoimmune, and infectious diseases, reports that its new distributing partner, New Vitality, has placed and received its first order of NPHC’s all-natural, non-addictive pain reliever, Nyloxin®, a homeopathic drug that utilizes proteins from cobra venom.
The order was pursuant to New Vitality’s successful test radio campaign to gauge market acceptance of the product. The radio test was the first broad exposure to NPHC’s Nyloxin brand and received positive feedback from U.S. consumers.
“It’s been a pleasure working with New Vitality as they create awareness for our products,” NPHC CEO Rik J Deitsch stated in the press release. “The radio advertising ran in major markets across the U.S. over several weeks, with a consumer response that was positive enough to warrant the first orders from New Vitality. As things progress, we expect to expand the relationship and have already worked with New Vitality on our launch of Pet Pain-Away, our product for pain in companion animals.”
Nyloxin™ is available in an easy-to-use oral spray for treating a wide range of pain, such as lower back pain, migraines, neck aches, shoulder pain, cramps, and neuralgia, as well as a topical gel for treating repetitive stress, arthritis, and joint pain.
For more information visit www.NutraPharma.com or www.Nyloxin.net
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment